Alicia K. Morgans

1 month ago | urologytimes.com | Alicia K. Morgans |Benjamin P. Saylor

Findings of a recent study point to the importance of calculating prostate-specific antigen doubling time (PSADT) in patients with high-risk, biochemically recurrent prostate cancer.1The data were presented at the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium in San Francisco, California, by Alicia Morgans, MD, MPH, a genitourinary medical oncologist and the director of the Survivorship Program at Dana-Farber Cancer Institute in Boston, Massachusetts.

1 month ago | urologytimes.com | Alicia K. Morgans |Benjamin P. Saylor

In this video, Alicia Morgans, MD, MPH, shares insights from the study “Impact of physicians’ awareness of prostate-specific antigen doubling time (PSADT) on treatment (Tx) decisions in high-risk (HR) biochemically recurrent (BCR) prostate cancer (PC),” which she presented at the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium in San Francisco, California.

Oct 16, 2024 | nature.com | Tanya B. Dorff |Alicia K. Morgans

AbstractNovel therapies for metastatic castration-resistant prostate cancer (mCRPC) have improved patient outcomes. However, there is uncertainty on the optimal selection of therapeutic agents for subsequent lines of therapy. We conducted a comprehensive review of published evidence from pivotal clinical trials and recent guidelines for the treatment of mCRPC. We further identify gaps in knowledge and areas for future research.

Sep 24, 2024 | onclive.com | Alicia K. Morgans

Alicia Morgans, MD, MPH, genitourinary medical oncologist, medical director, Survivorship Program, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School, discusses the recent adjustments to Medicare Part D rules and how they impact on out-of-pocket costs for patients with prostate cancer. The Inflation Reduction Act has made several recent adjustments to Medicare Part D rules, including lowering out-of-pocket prescription drug costs for Medicare Part D.

Sep 18, 2024 | onclive.com | Alicia K. Morgans

Alicia Morgans, MD, MPH, genitourinary medical oncologist, medical director, Survivorship Program, Dana-Farber Cancer Institute, and associate professor of medicine, Harvard Medical School, discusses previously reported data from the phase 3 ARAMIS trial (NCT02200614), highlighting the rationale for conducting a follow-up analysis of the study in nonmetastatic castration-resistant prostate cancer (nmCRPC).